Minneapolis – October 30, 2013 – CVRx, Inc., a privately held medical device company, has closed on an additional $12 million under its Series F financing. This brings the total raised in the ...
The method will be incorporated into Neurofarmagen, a genetic test which helps doctors identify the most appropriate treatment for each neuropsychiatric patient
Results presented include analyses of predictive biomarkers and novel mechanisms of resistance to targeted therapies, as well as the early results of whole exome and transcriptome sequencing in col...
On February 2, 2012 it was announced that Integromics®, a market leader in IT solutions provision for life sciences in the field of genomics and proteomics, entered into a partnership with Professo...